The discovery of new mechanism of hepatitis C helps to improve new effective drugs

Recently, researchers from Osaka University redefined the new mechanism of hepatitis C (HCV) transmission from the angle of enhancing the liver function. They used a mouse model to demonstrate that when a particular enzyme is inhibited, virus particles produced by HCV would be reduced so as to improve pathological liver disease, and thus they determined a new drug target. Some recombinant human proteins also can treat the disease.

Currently, nearly 200 million people worldwide are infected with hepatitis C virus. It can cause fatty liver, cirrhosis, liver cancer and other diseases after infection with hepatitis C virus. In Japan, hepatitis C virus is the culprit which causes liver cancer. Although researchers now have developed many enzymes against the copy of hepatitis C to clear HCV, the presence of a lot of viruses with drug resistance and cancer incidence after clearing the virus can't be explained. So far, removing the core protein of virus in host cell is still the main method, but through many research using recombinant mouse proteins and recombinant rat proteins, we are still not very clear about the mechanism in it.

Associate professor Toru Okamoto and Yoshiharu Matsuura at the Institute of Microbial of Osaka University were responsible for the study. When the enzyme SPP is inhibited, the virus particles are reduced, finally improving the pathological liver disease.

γ- secretase inhibitor is a kind of drugs are now developed and used in the Alzheimer's, but from which the researchers discovered a chemical that can inhibit the enzyme SPP. At the same time, they found that the removal of core proteins mainly relied on the enzyme TRC8, and this enzyme is very easy to be degraded. If the degradation ability is inhibited, the cell would receive great harm due to the stress effect of endoplasmic reticulum, and then the synthetic proteins can't properly fold, which leads to cell damage. Therefore, this degradation process is a novel protein controlling mechanism. The SPP mouse model will enhance the treatment outcomes of patients.

The study showed that SPP inhibitor is a new therapeutic drug of hepatitis C. Besides, observing the formation of proteins through SPP / TRC8 signaling pathway also improves the development of a series of drugs. Flarebio provides you with good-quality recombinant proteins such as recombinant INSRR at good prices.